CLOBETASOL PROPIONATE CREAM USP, 0.05%
MARKETED BY
: Alembic
COMPARE TO: Fourgera’s Temovate Cream, 0.05%
Clobetasol propionate cream, 0.05%, offers a new topical option for patients with various skin conditions. The generic, superhigh-potency corticosteroid formulation is indicated for the relief of inflammatory and pruritic manifestations, including allergic reactions, eczema, and psoriasis. Recently approved by the FDA, the cream had a market value of about $57 million for the 12 months ended in September 2019, according to data from IQVIA. Common adverse effects include burning, dryness, itching, rash, and stinging at the application site when first applied.
FOR MORE INFORMATION: alembicpharmaceuticals.com




TABLETS, 600 MG
MARKETED BY: Alembic
COMPARE TO: Pfizer’s Zithromax Tablets, 250 mg and 500 mg
The FDA recently approved Alembic’s generic azithromycin tablets in a strength of 600 mg, indicated for mild to moderate infections caused by bacteria in chronic bronchitis in adults, acute bacterial sinusitis in adults, uncomplicated skin infections in adults, urethritis and cervicitis in adults, genital ulcer disease in men, acute otitis media in pediatric patients, community-acquired pneumonia, and pharyngitis/tonsillitis in adults and pediatric patients. The 250- and 500-mg doses of the tablets had a market value of about $129 million for the 12 months ended in September 2019, according to data from IQVIA.
FOR MORE INFORMATION: alembicpharmaceuticals.com




CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS
MARKETED BY
: Upsher-Smith
COMPARE TO: Concordia’s Kapvay Extended-Relief Tablets
Upsher-Smith is launching clonidine hydrochloride extended-release tablets in 0.1-mg strength, indicated for the treatment of attentiondeficit/hyperactivity disorder both as a monotherapy and as adjunctive therapy to stimulant  medications. In a fixed-dose monotherapy trial, common adverse reactions included gastrointestinal viral (0% in 0.2 mg/day, 5% in 0.4 mg/day), headache (5% in 0.2 mg/day, 2% in 0.4 mg/day), somnolence (2% in 0.2 mg/day, 3% in 0.4 mg/day), and upper abdominal pain (0% in 0.2 mg/day, 6% in 0.4 mg/day).
FOR MORE INFORMATION: upsher-smith.com




ESOMEPRAZOLE MAGNESIUM DELAYEDRELEASE CAPSULES
MARKETED BY
: Camber Pharmaceuticals
COMPARE TO: AstraZeneca’s Nexium
Camber has launched esomeprazole magnesium delayed-release capsules for the treatment of a damaged esophagus, gastroesophageal reflux disease, heartburn, and stomach ulcers. The capsules are available in 20- and 40-mg
doses and 30-, 90-, and 1000-count bottles. Acid reflux can be aggravated by alcohol, coffee, fatty or fried foods, overeating, smoking, and some medications, such as aspirin. Adverse effects of esomeprazole can include diarrhea, headache, and nausea.
FOR MORE INFORMATION: camberpharma.com